News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
746,163 Results
Type
Article (54910)
Company Profile (513)
Press Release (690740)
Section
Business (218259)
Career Advice (2838)
Deals (37406)
Drug Delivery (105)
Drug Development (86685)
Employer Resources (180)
FDA (17065)
Job Trends (15957)
News (369872)
Policy (35647)
Tag
Academia (2904)
Alliances (53401)
Alzheimer's disease (1310)
Approvals (16964)
Artificial intelligence (131)
Bankruptcy (381)
Best Places to Work (12123)
Biotechnology (377)
Breast cancer (111)
Cancer (956)
Cardiovascular disease (86)
Career advice (2379)
Cell therapy (214)
Clinical research (68213)
Collaboration (344)
Compensation (160)
COVID-19 (2749)
Data (855)
Diabetes (140)
Diagnostics (6483)
Drug pricing (94)
Earnings (87251)
Employer resources (157)
Events (117613)
Executive appointments (252)
FDA (17507)
Funding (304)
Gene therapy (167)
GLP-1 (648)
Government (4777)
Healthcare (20066)
Infectious disease (2827)
Inflammatory bowel disease (113)
Interviews (549)
IPO (16929)
Job creations (4160)
Job search strategy (1975)
Layoffs (462)
Legal (8739)
Lung cancer (169)
Manufacturing (164)
Medical device (13844)
Medtech (13849)
Mergers & acquisitions (20462)
Metabolic disorders (397)
Neuroscience (1574)
NextGen Class of 2024 (7240)
Non-profit (4899)
Northern California (1210)
Obesity (237)
Opinion (224)
Patents (101)
People (61350)
Pharmaceutical (92)
Phase I (21180)
Phase II (29929)
Phase III (22346)
Pipeline (206)
Postmarket research (2939)
Preclinical (9194)
Radiopharmaceuticals (252)
Rare diseases (197)
Real estate (6561)
Regulatory (23420)
Research institute (2591)
Resumes & cover letters (452)
Southern California (1094)
Startups (3918)
United States (12115)
Vaccines (606)
Weight loss (193)
Date
Last 7 days (814)
Last 30 days (2813)
Last 365 days (37594)
2024 (31885)
2023 (41997)
2022 (53335)
2021 (58011)
2020 (56781)
2019 (50016)
2018 (37828)
2017 (34907)
2016 (34803)
2015 (40904)
2014 (35079)
2013 (30509)
2012 (32437)
2011 (32874)
2010 (31160)
Location
Africa (920)
Arizona (203)
Asia (42529)
Australia (7691)
California (2806)
Canada (1179)
China (213)
Colorado (120)
Connecticut (129)
Europe (95011)
Florida (392)
Georgia (101)
Illinois (344)
Indiana (185)
Kansas (100)
Maryland (544)
Massachusetts (2307)
Michigan (147)
Minnesota (264)
New Jersey (838)
New York (855)
North Carolina (752)
Northern California (1210)
Ohio (126)
Pennsylvania (750)
South America (1313)
Southern California (1094)
Texas (397)
Washington State (339)
746,163 Results for "windtree therapeutics inc formerly known as discovery laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Windtree Therapeutics Regains Compliance with Nasdaq - May 07, 2024
Windtree Therapeutics, Inc. announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
May 7, 2024
·
5 min read
Deals
Windtree Therapeutics Announces Reverse Stock Split - April 18, 2024
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”).
April 18, 2024
·
7 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Windtree Therapeutics, Inc. today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.
January 31, 2024
·
6 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Business
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
April 17, 2024
·
16 min read
Deals
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Medicure Inc. announces it has signed an asset purchase agreement with CanAm Bioresearch Inc. for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use.
June 24, 2024
·
9 min read
Press Releases
Windtree To Present at the ThinkEquity Conference on October 30th
October 22, 2024
·
5 min read
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Deals
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Windtree Therapeutics, Inc., announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor.
April 8, 2024
·
9 min read
1 of 74,617
Next
